Esophageal Cancer Clinical Trial
Official title:
A Multimodal Prehabilitation Feasibility Study for Older Adult Patients at High Risk for Poor Postoperative Outcomes Prior to Esophageal Cancer Surgery
The goal of this research study is to investigate the feasibility of implementing a prehabilitation program that aims to improve a patient's physical, nutritional, and sleep health before surgery in an older, at-risk group with esophageal cancer.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 31, 2026 |
Est. primary completion date | October 18, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - 65 years of age and over - Adult male or non-pregnant female volunteers - Completed neoadjuvant chemotherapy or radiotherapy for esophageal cancer - At least four weeks to esophageal cancer surgery - Without skin conditions that preclude wearing sensors - Able to speak English and consent Exclusion Criteria: - Participants in any other interventional study that may bias results or limit study adherence during our study - Dietary restrictions that prevent consumption of nutritional supplements - Women who are pregnant, nursing, or at risk of becoming pregnant - Profound physical disability (for example, quadriplegia) that precludes participation in any aerobic or strength training. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sarcopenia | Assessed by baseline Computed Tomography (CT) scan of the thorax. | At baseline | |
Other | Malnutrition | Assessed by the Perioperative Nutrition Screen (PONS) Risk Score, a modified version of the malnutrition universal screening tool, which determines the presence of nutrition risk based on BMI, recent body weight loss, decrement of dietary intake, and preoperative albumin concentration. | At baseline visit and second measure at post-operative 1 day visit | |
Other | Patient-Reported Sleep Measures | Assessed by the International Physical Activity Questionnaire (IPAQ), a 27-item self-reported measure of physical activity. | At baseline visit and second measure at post-operative 1 day visit | |
Other | Hand Grip Test | Assessed by change in baseline and post-operative Hand Grip tests using a hand-held dynamometer. An average score is calculated using measurements from both hands. | At baseline visit and second measure at post-operative 1 day visit | |
Other | BMI | Assessed by change in baseline and post-operative height and weight. | At baseline visit and second measure at post-operative 1 day visit | |
Other | Energy expenditure | Assessed by change in baseline and post-operative Metabolic Cart, or indirect calorimetry. | At baseline visit and second measure at post-operative 1 day visit | |
Other | 6-Minute Walk Test | Assessed by a baseline and a post-operative 6-Minute Walk Test, a sub-maximal exercise test used to assess aerobic capacity and endurance. | At baseline visit and second measure at post-operative 1 day visit | |
Other | Patient-Reported Measures on Physical Function Score | Assessed by Activity Measure for Post-Acute Care (AM-PAC), a standardized assessment used to measure the physical function and functional status of patients. The AM-PAC consists of 13 tests that divided into lower and upper extremity function, gait and balance and activities of daily living and instrumental activities of daily living. Also assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF), a 45-item self-reported measure to evaluate physical function. | At baseline visit and second measure at post-operative 1 day visit | |
Primary | Enrollment Rate (Feasibility) | Number of eligible patients who enroll in study | At screening | |
Primary | Completion Rate (Feasibility) | Defined as the number of patients who complete study procedures. | 30 days | |
Secondary | Nutrition Compliance Rate (Feasibility) | Comparison of number of nutritional supplements consumed compared to number of nutritional supplements prescribed as determined from daily check-ins. A cut-off value of 80% will be used to indicate compliance. | 5 days | |
Secondary | Physical Function Compliance Rate (Feasibility) | Comparison of the total minutes of physical function completed compared to the total minutes of physical function prescribed as determined from daily check-ins and wearable device. A cut-off value of 80% will be used to indicate compliance. | 30 days | |
Secondary | Sleep Health Compliance Rate (Feasibility) | Comparison of the average daily hours of sleep duration, minutes of wake after sleep onset, and variability in sleep timing, achieved compared to prescribed as determined from actigraphy. A cut-off value of 80% will be used to indicate compliance. | 30 days | |
Secondary | Actigraphy Compliance Rate (Feasibility) | Total daily hours of actiwatch/wearable device wear-time. A cut-off value of 80% will be used to indicate compliance. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |